Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01231269|
Recruitment Status : Unknown
Verified September 2010 by Universitaire Ziekenhuizen Leuven.
Recruitment status was: Active, not recruiting
First Posted : November 1, 2010
Last Update Posted : January 4, 2017
Whole body diffusion-weighted imaging is a functional magnetic resonance imaging technique that characterizes tissue by probing changes in water diffusion secondary to differences in the tissue microstructure. These changes in water diffusion result in differences in signal intensity on diffusion-weighted-images that are quantified with the apparent diffusion coefficient (ADC). In malignant lesions, the extravascular extracellular space (EES) will be diminished, due to the increased number of cells. This will restrict water diffusion, identified by increased signal intensity (SI) on native DWI images and low ADC. Several studies indicate the value of DWI for differentiation of benign and malignant lymph nodes, detection of tumor recurrence and for ADC-based prediction of treatment outcome in various solid tumours (Koh DM et al, Am J Roentgenol 2007).
Patients with a new diagnosis of Hodgkin or Non-Hodgkin Lymphoma (only diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and PTLD) will be included in the study. These patients will receive a WB-DWI scan before treatment, once or twice during treatment (depending on the type of lymphoma) and after the completion of the treatment. The MRI scan will be performed on a 3 Tesla-MRI system without contrast administration and without exposing the patient to radiation.
Whole body diffusion-weighted images will be prospectively interpreted by two experienced radiologists, blinded to all clinical and imaging data. Findings will be correlated to FDG-18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose , biopsies performed in clinical routine (bone marrow always - soft tissue lesions if indicated) and imaging follow-up.
The purpose of this study is:
- to evaluate Whole body diffusion-weighted imaging for staging of lymphoma
- to evaluate Whole body diffusion-weighted imaging as an early predictive biomarker for treatment outcome
- to evaluate Whole body diffusion-weighted imaging for differentiating residual tumor from post therapy changes
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma (Follicular, Diffuse B-cel Lymphoma, PTLD and Mantle Cel Lymphoma)||Other: MRI||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2017|
MRI scan without administration of contrast/without radiation
- disease stage [ Time Frame: 4 years ]Lesions are characterized as benign or malignant based on signal intensity and ADC values, enabling correct determination of tumor extent (staging).
- progression free survival [ Time Frame: 6 years ]We will investigate whether there is a correlation between ADC and signal intensity changes during therapy and progression free survival
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01231269
|University Hospital Leuven|
|Leuven, Vlaams-Brabant, Belgium, 3000|
|Principal Investigator:||vincent vandecaveye, MD PhD||University Hospitals Leuven|